EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) were developed to treat patients with EGFR somatic activating mutations; they were first discovered to underpin NSCLC responsiveness to gefitinib in 2004 (Lynch et al., 2004; Mayo et al., 2012).